BioNTech to acquire Biotheus for $950m.

BioNTech, a clinical-stage biotechnology company, agreed to acquire Biotheus, a Chinese cancer drugmaker, for $950m. “The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies. We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors. We are committed to advancing its research and development in combination with our investigational mRNA vaccines, targeted therapies, and immunomodulators with the aim of enhancing outcomes for patients with solid tumors," Ugur Sahin, BioNTech CEO and Co-Founder.